ACTRIIA-Fc (Sotatercept) Reverses Pulmonary Vascular Remodeling to Attenuate Pulmonary Arterial Hypertension (PAH) by Rebalancing TGF-b/BMP Signaling in a Preclinical Model

Abstract

Acknowledements Paul B. Yu, M.D., Ph.D. Research Support: Acceleron ActRIIA-Fc reverses pulmonary vascular remodeling, improves pulmonary hemodynamics, and improves RV function by reducing Smad2/3 overactivation and rebalancing activin/BMP signaling in pulmonary arteries and RV. These changes could potentially translate to distinct clinical benefit over currently available therapies for PAH. Right Ventricular Systolic Pressure